NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Atossa Therapeutics, Inc. (ATOS) Stock Analysis

Atossa Therapeutics, Inc. (ATOS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ATOS

$2.52

−$0.01 (−0.40%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ATOS with… →

ATOS Key Statistics

As of Sep 4, 2026
Trading
Open
$2.51
Previous Close
$2.53
Day's Range
2.50–2.60
52-Week Range
1.70–19.35
Volume
28.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.27
Valuation
Market Cap
$25.15M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.31
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$34.77M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
9.98M
1-Year Return
−78.18%
Dividend and dates
Avg Volume
155.77K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ATOS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−71.53%
2025−37.23%
2024+6.82%
2023+66.04%
2022−66.88%
2021+68.42%
2020−39.49%
2019+53.92%
2018−67.31%
2017−81.56%
2016 (partial year)−65.19%

As of September 4, 2026.

ATOS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$34.77M—
2024$0.00−$25.50M—
2023$0.00−$30.09M—
2022$0.00−$26.96M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$37.14M−$34.77M—
2024$0.00—−$27.62M−$25.50M—
2023$0.00—−$31.38M−$30.09M—
2022$0.00—−$27.69M−$26.96M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ATOS Valuation vs Biotechnology Median

Median of 656 stocks
MetricATOSBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Atossa Therapeutics, Inc. (ATOS) carries a market capitalisation of $25.15M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 16 employees.

The most recent close on file for ATOS is $2.52, dated September 4, 2026. That is −$0.01 (−0.40%) against the previous close. Over the past 52 weeks the price has ranged from $1.70 to $19.35. The latest close sits 48.24% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $34.77M. Profit margin runs at 0%. Trailing earnings per share are −4.31.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 1.28. Annualized volatility over the trailing 10 years is 155.71%. Over the trailing twelve months the price has returned −78.18%. Measured over 10 years, that is −40.26% a year compounded.

Growth & Income

No dividend is on file for ATOS.

The strongest complete calendar year on file is 2021 at +68.42%; the weakest is 2017 at −81.56%. Of the 9 complete calendar years on file, 4 finished higher. 2026 is still running; the price is −71.53% year to date.

Peer Comparison

Atossa Therapeutics, Inc. (ATOS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Atossa Therapeutics, Inc. ATOS $25.15M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Atossa Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Visit website →